MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. BFLY
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Butterfly Network (BFLY) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Butterfly Network
NYSE•Healthcare•Medical Devices
$6.66-0.85(-0.11%)Market open
Market Cap
$1.64B
P/S
13.3x
P/B
8.9x

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. The company offers Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging on a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; Butterfly Move, merging the mobility of a handheld with the stability of a full cart system; and iQ+ Bladder, a specialty product for bladder scanning market. It also provides Compass AI which offers one system to connect every device, workflow, and department; ScanLab, an AI-powered educational platform that provides written walkthroughs and reference imagery to guide real-time educational scanning; and Butterfly iQ+/iQ3 Vet, a third generation handheld ultrasound system. It sells and markets its products through a direct sales force, distributors, and e-commerce channels. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

D

How this company scores

WeakMetricSide Score: 49/100

Grade capped at D — Interest coverage below 1× (-50.9x) — earnings cannot cover interest. Strongest: Growth (20/25); weakest: Cash & Earnings Quality (5/25).

Profitability17/25
Growth20/25
Balance Sheet & Red Flags7/25
Cash & Earnings Quality5/25
Strengths
Growing revenueLong cash runwayProfit converts from growthConsistent growth
Grade capped at D
  • Interest coverage below 1× (-50.9x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 13.3x5y range 5.6x – 20.8x
P/S 13.3x · above its 20-quarter median

Currently above its 20-quarter median.

P/B · 8.9x5y range 0.8x – 12.3x
P/B 8.9x · above its 20-quarter median

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume
Market Cap $1.64B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$123.25M
7Q
Q. Revenue
$32.60M
52%
TTM EBITDA
$-50.99M
3Q
TTM Op. Income
$-57.83M
4Q
Q. Op. Income
$-13.58M
4Q
TTM Net Income
$-53.69M
4Q
Q. Net Income
$-12.81M
62%
EPS
$-0.05
62%
Shares Out.
$266.50M
7Q
$123.25M in TTM revenue grew 39.3% YoY, reaching $32.60M last quarter. TTM EBITDA of $-50.99M and TTM operating income of $-57.83M show growth is flowing through to the bottom line. However, net income is negative at $53.69M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
73.0%
4Q
EBITDA Margin
-36.7%
4Q
Op. Margin
-41.7%
4Q
Net Margin
-39.3%
4Q
Op. margin of -41.7% is up 121.8% YoY — cost efficiency is improving. Net margin at -39.3% and gross margin of 73.0% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 4 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
N/A
P/S Ratio
13.3x
138%
P/B Ratio
8.9x
266%
P/S of 13.3x and P/B of 8.9x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$287.98M
1%
Cash
$122.30M
3Q
Long-Term Debt
N/A
Book Value
$184.44M
6Q
D/E Ratio
N/A
Debt/EBITDA
N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$-2.27M
22%
TTM Free Cash Flow
$-27.55M
0%
FCF Margin
-22.4%
28%
FCF / Net Income
0.5
3Q
TTM FCF of $-27.55M on $-2.27M in operating cash flow. The FCF / Net Income ratio of 0.5x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is down 0% — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General

Cash Burn

Red Flag

The last 4 consecutive quarters had negative FCF — the company is burning cash and may need external funding.

Share Dilution

Red Flag

Shares outstanding increased 24.9% — significant dilution, likely from stock compensation or capital raises.